Company intelligence / Profile preview

Shanghai Huaota Biopharmaceutical Co., Ltd.

Shanghai, Shanghai, Chinahuabobio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Multiple products in clinical development with HB-0017 (IL-17A inhibitor) in Phase 3 for psoriatic arthritis, Recibokibart (IL-36R inhibitor) in Phase 2/3 for generalized pustular psoriasis, HB002.1M (VEGF inhibitor) in Phase 2 for diabetic macular edema, and several other candidates in Phase 1/2 trials

Therapeutic areas: GastroenterologyPulmonologyRheumatologyOphthalmologyImmunologyDermatologyOncology
Modalities: Monoclonal antibodiesBispecific antibodiesFusion proteinsAntibody drug conjugates (ADC)Small molecule drugs
Industry: Biotech

Drug pipeline

10 assets

HB0017

9 more assets in the full pipeline.

Request access →

Partnerships

Korea Eutilex Co., Ltd.US Oncobiologics Inc.Shanghai Junshi Biosciences Co., Ltd.

Beyond the preview

Go deeper on Shanghai Huaota Biopharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Huaota Biopharmaceutical Co., Ltd..

Explore the full profile